



FIG. 1b



FIG. 1a




FIG. 1c




FIG. 1d

3/17




FIG. 2c

FIG. 2b

FIG. 2a




FIG. 2d

FIG. 2e




FIG. 3




FIG. 4

7/17




FIG. 5

P 815 TARGETS (T)




FIG. 6A

■ E:T RATIO 60
 □ E:T RATIO 30
 ▤ E:T RATIO 15
 ▨ E:T RATIO 7.5




FIG. 6B

10/17




FIG. 7




FIG. 8a




FIG. 8b




FIG. 9

Fluorescence Intensity
(log Scale)






FIG.10


Insulin + hybridoma




allo MLR Proliferation




allo MLR IL-2



allo MLR +/- anti B7





- A**
- ▲ L1210+P815 (7X)
 - ▼ L1210+HY38/GM-CSF (7X)
 - ◆ P815+P815 (7X)
 - P815+HY38/GM-CSF (3X)
 - P815+HY38/GM-CSF (7X)
- B**
- ▼ untreated mice + P815 ascite
 - surviving mice treated with HY38/GM-CSF (7X) + P815 ascite
 - surviving mice treated with HY38/GM-CSF (3X) + P815 ascite

